INTRODUCTION
Shedding is defined as "releasing and/or separating something". The phenomenon of shedding can be found in biological systems, exemplified by viral shedding and receptor shedding. Viral shedding is the process of expelling virus particles from the body, whereas receptor shedding is the process whereby the extracellular domain of transmembrane proteins is cleaved (separated) and released from the cell surface. Receptor shedding has been implicated in a number of common regulatory mechanisms. For example, epidermal growth factor receptor (EGFR) ligands are synthesized as transmembrane proteins, and shedding of the extracellular domain (ectodomain) is required for the release of EGF and the regulation of diverse functions, including development, growth, and differentiation (1). The ectodomain shedding of membrane-tethered EGFR ligands are mediated by protease TACE/ ADAM17 (2) and ADAM12 (3). During osteoclastogenesis, receptor activator of NF-κΒ ligand (RANKL) is cleaved proteolytically and released from the cell surface by tumor necrosis factor-α (TNF-α)-converting enzyme (4). Extracellular domain shedding is also a characteristic of other growth factors, such as transforming growth factor-α (TGF-α) and TNF-α as well as cell adhesion molecules, including L-selectin (5) and E-cadherin (6). Thus, the process of shedding is an important mechanism for controlling diverse cellular functions.
Recently, receptor shedding has been identified as a common mechanism in various diseases, including cancer and cardiovascular disease. For example, proteolysis of the receptor for advanced glycation end products (RAGE) (7-9) is able to suppress the development of Alzheimer's disease; therefore, the modulation of RAGE proteolysis is considered a potential novel therapeutic target for the treatment of Alzheimer's disease (9, 10). Stimulation of platelet 5-hydroxytryptamine (5-HT) receptors (5-HT2ARs) by circulating serotonin (5-HT) induces TACE-mediated shedding of GPIbα, which is capable of modulating cardiovascular disease (11). A high level of the P-cadherin soluble fragment, which is possibly released via extracellular domain shedding, has been correlated with an increased risk for breast cancer (12). A soluble fragment of the Type III TGF-β receptor generated by ectodomain shedding has been shown to suppress the invasion of non-small cell lung cancer (13), and the progression of pancreatic cancer (14). In addition, the shed soluble domain of the endothelial-specific Tie2 receptor might be a prognostic indicator in patients with acute myeloid leukemia (15); and serum soluble interleukin 2 receptor might act as a new biochemical marker of neoplasm activity in adults and children (16). On the other hand, tissue inhibitor metalloproteinases-3 (TIMP-3), which inhibits the shedding of TNF-α receptors, Fas, and p55TNF receptor 1, might facilitate apoptosis of cancer cells. Although is uncertain whether shedding is a direct cause of cancer, it is clear that shedding is an important regulatory mechanism in carcinogenesis.
Syndecans and cancer
Syndecans, a family of cell surface heparansulfate proteoglycans, are known to play critical roles in cancer cell biology. The biological functions of syndecans as cell surface receptors have been well summarized in several excellent reviews (17) (18) (19) . Each syndecan appears to have different role in the regulation of cancer-related processes. Syndecan-1 plays an important role in the growth, survival, vasculogenesis, and metastasis of various cancers, including myelomas (20) and breast (21), bladder (22), ovary (23), prostate (24) and colon cancers (25). For instance, knockdown of syndecan-1 using small interfering RNAs (shRNA) promotes apoptosis of myeloma cells and dramatically diminishes tumor cell growth (20). Knockdown of syndecan-1 also decreases vascular endothelial growth factor-A (VEGF-A) levels and vasculogenesis in mouse models (20). Consistent with this, overexpression of syndecan-1 has bee shown to induce approximately a twofold increase in the proliferation of endometrial cancer cells (26). Syndecan-1 mRNA levels are up-regulated in pancreatic cancer in association with accelerated tumor growth, as determined by in situ hybridization and immunohistochemistry (27) .
In contrast to syndecan-1, which has been implicated in a variety of cancer types, the role of syndecan-2 seems to be limited to melanomas and colon and prostate cancers. Syndecan-2 is dramatically overexpressed in melanomas and several colon carcinoma cell types, and up-regulation of syndecan-2 is believed to increase the tumorigenic activity of these cells. Moreover, colon cancer cells cultured on syndecan-2 ectodomain or syndecan-2 antibody show increased adhesion and spreading (28). Syndecan-2 is also overexpressed in about 90% of prostate cancer patients, and the increased syndecan-2 expression enhances the growth of prostate tumor cells (29). In contrast to other syndecans, which generally function as tumor promoters, syndecan-4 apparently functions as a tumor suppressor. Syndecan-4 promotes focal adhesion formation, resulting in increased cell adhesion but decreased cell migration, effects that collectively reduce cancer cell activity (30). Those reports have all shown that syndecans play a critical role as cell surface receptors in cancer cells. Interestingly, the presence of a dibasic peptide sequence adjacent to the plasma membrane in all syndecans predicted that the extracellular domain of syndecan could be cleaved by extracellular proteases. This has since been experimentally demonstrated and recent evidence points to shedding of the extracellular domain as a prominent aspect of the function of syndecans. Considered in light of the function of syndecans as cell surface receptors, syndecan shedding seemingly poses a dilemma. However, syndecan shedding might constitute an additional level for controlling the function of syndecans, providing a means to attenuate and/or regulate the amplitude and/or duration of syndecan signals by modulating the activity of syndecans as cell surface receptors.
Syndecan shedding enzymes
Since syndecan shedding involves releases of the extracellular domain, it would most likely be mediated by extracellular proteases. Several matrix metalloproteases (MMPs), zinc-dependent endopetidases that play an important role at different stages of cancer progression, have been reported to regulate the shedding of syndecans. MMP-9 has been implicated in the stromal cell-derived factor-1 (SDF-1)-induced shedding of syndecan-1 and syndecan-4 in HeLa cervical cancer cells (31). In these cells, siRNA-mediated knockdown of MMP-9 reduced shedding of syndecan-1 and syndecan-4, despite the continued presence of SDF-1, confirming that MMP-9 mediates shedding of syndecan-1 and syndecan-4. There is also evidence for the involvement of other MMPs. For example, Chen et al showed that epithelial injury induced syndecan-1 shedding from the epithelium of wild-type mice but not from the epithelium of MMP-7 knockout mice (32); and Endo et al showed that membrane type matrix metalloproteinase-1 (MT1-MMP) promoted syndecan-1 shedding through the preferential cleavage of syndecan-1 core protein Gly245-Leu246 peptide bond. Indeed syndecan-1 contains a general consensus sequence for cleavage by MMP-7, MMP-9 and MT1-MMP (33). The shedding of syndecan-3 has also been reported in Schwann cells obtained from the sciatic nerves of 2-4 day-old rats (34). This shedding is reduced in cells treated with the MMP inhibitor Batimastat (BB-94) (34), providing evidence for the involvement of MMPs in mediating syndecan-3 shedding.
ADAMTS1, a member of the disintegrin-like and metalloprotease with thrombospondin type-1 motifs family is also known to cleave the syndecan-4 ectodomain. After co-transfecting 293T cells with ADAMTS1 and an N-terminally HAtagged full-length syndecan-4 construct, a soluble fragment (approximately 6-7 kDa) of HA-tagged syndecan-4 extracellular domain was detected in conditioned media (35). This shedding of syndecan-4 was reduced by BB-94, a metalloprotease inhibitor that partially inhibits the protease activity of ADAMTS1 (35). Moreover, shedding of both syndecan-1 and -4 was blocked by the peptide hydroxamates BB-2116 and BB-1101 (36), which are compounds that were originally designed to inhibit zinc-dependent MMPs.
ADAM17, a disintegrin and metalloproteinase family members, is also known to cleave syndecans. Production of soluble syndecan-1 and -4 was reduced in both ECV304 bladder carcinoma epithelial cells and A549 lung carcinoma epithelial cells by treatment with GW280264, an inhibitor of ADAM17 and ADAM10, but not by the ADAM10 inhibitor GI254023 (37). Similarly, the shedding of syndecan-1 and syndecan-4 is stimulated by the recombinant ADAM17 catalytic domain (37). In addition, siRNA-mediated knockdown of ADAM17 reduced shedding of syndecan-1 and syndecan-4 in ECV304 cells and A549 cells (37). ADAM17 activation also mediates release of soluble syndecan-1 and -4 into the bronchoalveolar fluid of
